ClinicalTrials.gg
CompletedNCT04622046Updated Jun 10, 2026Results posted

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

A Phase 3 interventional study of ALXN2060 in Symptomatic Transthyretin Amyloid Cardiomyopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 11 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Sex
All
01

Study summary

This prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a background of stable heart failure therapy.

Read the detailed description

Participants will receive ALXN2060 for 12 months (Part A). Following the last visit (Month 12) of Part A, participants will continue the study in Part B, which will last for an additional 18 months (30 months from Day 1), during which all participants will continue to receive oral treatment with ALXN2060. Following completion of Month 30 assessments in Part B, participants will be offered the opportunity to continue to receive ALXN2060 in the Extension Period, which will last until ALXN2060 is approved in Japan or for up to 24 additional months, whichever occurs first.

02

Conditions studied

  • Symptomatic Transthyretin Amyloid Cardiomyopathy
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype.
  2. History of heart failure evidenced by at least 1 prior hospitalization for heart failure or clinical evidence of heart failure without prior heart failure hospitalization manifested by signs or symptoms of volume overload or elevated pressures or heart failure symptoms that required or requires ongoing treatment with a diuretic.
  3. Class I-III symptoms due to ATTR-CM.
  4. On stable doses of cardiovascular medical therapy.
  5. Completed ≥ 150 meters on the 6MWT on 2 tests prior to Day 1.
  6. Left ventricular (LV) wall (interventricular septum or LV posterior wall) thickness ≥ 12 millimeters.
  7. Biomarkers of myocardial wall stress: N-terminal pro-brain-type natriuretic pep (NT-proBNP) level ≥ 300 picograms/milliliter (pg/mL).

Exclusion criteria

Exclusion Criteria:

  1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or within 90 days prior to screening.
  2. Hemodynamic instability at screening.
  3. Likely to undergo heart transplantation within a year of screening.
  4. Current treatment with marketed drug products and other agents for the treatment of ATTR-CM.
  5. Current treatment with calcium channel blockers with conduction system effects (for example, verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed.
  6. Confirmed diagnosis of light-chain (AL) amyloidosis.
  7. Biomarkers of myocardial wall stress: NT-ProBNP ≥ 8,500 pg/mL.
  8. Measure of kidney function, estimated by Modification of Diet in Renal Disease formula \< 30 mL/minute/1.73 meters squared.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    ALXN2060

    Participants will receive ALXN2060.

    Drug: ALXN2060

Interventions

  • ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.

    Also known as: AG10, Acoramidis

06

What researchers measure

Primary outcomes

  1. Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)

    The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at 12 months and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.

    Time frame: Baseline, Month 12

  2. Parts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period

    CV-related hospitalization was defined as the mean number of CV-related hospitalizations per participant per year over a 30-month period. CV-related hospitalizations were also reported as adverse events and were reviewed and adjudicated by an independent Clinical Events Committee (CEC).

    Time frame: 30 months

  3. All-cause Mortality (ACM) Over A 30-month Period

    ACM was assessed as time from the date of first initiation of study treatment to the date of death during a 30-month period, and was analyzed using Kaplan-Meier analysis. Data are reported for the number of participants with ACM over the 30-month period.

    Time frame: 30 months

Secondary outcomes

  1. Parts A and B: Change From Baseline In Distance Walked During The 6MWT

    The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at specified timepoints and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.

    Time frame: Baseline, Months 6, 9, 18, 24 and 30

  2. Parts A and B: Change From Baseline In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)

    The KCCQ is a 23-item questionnaire developed to measure health status and health-related quality of life in participants with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how their heart failure impacts their quality of life. The overall summary score ranged from 0-100, with higher scores indicating better health status. Data presented are for change from baseline to specified timepoints. Least squares mean change from baseline data were adjusted for baseline measures and visits.

    Time frame: Baseline, Months 6, 9, 12, 18, 24 and 30

  3. Parts A and B: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation

    A treatment-emergent AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention that occurred after first dose. A treatment-emergent SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect that occurred after first dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Month 30

  4. Parts A and B: Change From Baseline In Serum Transthyretin (TTR) Concentration

    Least squares mean change from baseline derived from with visits and baseline serum TTR as a covariate. Other covariates were included as needed.

    Time frame: Baseline, pre-dose on Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30

  5. Parts A and B: Change From Baseline In TTR Stabilization

    TTR stabilization was measured using fluorescent probe exclusion (FPE). Data presented are for change from baseline in FPE percentage stabilization.

    Time frame: Baseline, Pre-dose Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30

07

Results

Posted Dec 16, 2024

Participant flow

Intervention Period (Part A + Part B)
Participant flow — Intervention Period (Part A + Part B)
MilestoneALXN2060
Started25
Received at least 1 dose of study drug25
Completed22
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Extension Period
Participant flow — Extension Period
MilestoneALXN2060
Started21
Completed13
Not completed8
Withdrew: Adverse event4
Withdrew: Death1
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryPart A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)

The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at 12 months and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · meters
Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)
metersALXN2060
Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)-3.86 ± 9.182
PrimaryParts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period

CV-related hospitalization was defined as the mean number of CV-related hospitalizations per participant per year over a 30-month period. CV-related hospitalizations were also reported as adverse events and were reviewed and adjudicated by an independent Clinical Events Committee (CEC).

Time frame:
30 months
Reported as:
Mean · CV-related hospitalizations
Parts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period
CV-related hospitalizationsALXN2060
Parts A and B: Number of Cardiovascular (CV)-Related Hospitalizations Over A 30-month Period0.1329 (0.0511 to 0.3457)
SecondaryParts A and B: Change From Baseline In Distance Walked During The 6MWT

The 6MWT measures how far a participant can walk in 6 minutes. Change from baseline was calculated as the difference between the distance walked during the 6MWT at specified timepoints and the distance walked during the 6MWT at baseline. To determine the baseline, at least 2 6MWTs were conducted \> 24 hours to ≤ 3 weeks apart prior to the first dose of ALXN2060. The baseline 6MWT is the average of the total distance walked by participants for the 2 qualifying 6MWTs that met all the protocol-defined criteria. Least squares mean change from baseline data were adjusted for baseline measures and visits.

Time frame:
Baseline, Months 6, 9, 18, 24 and 30
Reported as:
Least squares mean · meters
Parts A and B: Change From Baseline In Distance Walked During The 6MWT
metersALXN2060
Month 6-29.54 ± 9.316
Month 9-23.12 ± 11.610
Month 18-26.27 ± 12.532
Month 24-24.89 ± 8.534
Month 30-36.20 ± 10.798
SecondaryParts A and B: Change From Baseline In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)

The KCCQ is a 23-item questionnaire developed to measure health status and health-related quality of life in participants with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how their heart failure impacts their quality of life. The overall summary score ranged from 0-100, with higher scores indicating better health status. Data presented are for change from baseline to specified timepoints. Least squares mean change from baseline data were adjusted for baseline measures and visits.

Time frame:
Baseline, Months 6, 9, 12, 18, 24 and 30
Reported as:
Least squares mean · scores on a scale
Parts A and B: Change From Baseline In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)
scores on a scaleALXN2060
Month 60.94 ± 2.779
Month 9-1.73 ± 3.291
Month 122.71 ± 2.766
Month 18-5.34 ± 3.747
Month 24-0.68 ± 3.029
Month 30-6.97 ± 3.755
SecondaryParts A and B: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation

A treatment-emergent AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention that occurred after first dose. A treatment-emergent SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, or was a congenital anomaly/birth defect that occurred after first dose. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Month 30
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation
ParticipantsALXN2060
Treatment-emergent AE25
Treatment-emergent SAE12
AEs Leading to Treatment Discontinuation2
SecondaryParts A and B: Change From Baseline In Serum Transthyretin (TTR) Concentration

Least squares mean change from baseline derived from with visits and baseline serum TTR as a covariate. Other covariates were included as needed.

Time frame:
Baseline, pre-dose on Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30
Reported as:
Least squares mean · milligrams (mg)/deciliter (dL)
Parts A and B: Change From Baseline In Serum Transthyretin (TTR) Concentration
milligrams (mg)/deciliter (dL)ALXN2060
Day 14, Predose9.73 ± 0.886
Day 28, Predose9.13 ± 1.256
Month 3, Predose10.64 ± 1.056
Month 6, Predose9.61 ± 0.847
Month 9, Predose11.16 ± 0.744
Month 12, Predose11.80 ± 1.157
Month 15, Predose10.79 ± 1.347
Month 18, Predose10.12 ± 1.253
Month 21, Predose9.23 ± 0.704
Month 24, Predose11.06 ± 0.848
Month 27, Predose9.57 ± 1.020
Month 30, Predose9.36 ± 1.280
SecondaryParts A and B: Change From Baseline In TTR Stabilization

TTR stabilization was measured using fluorescent probe exclusion (FPE). Data presented are for change from baseline in FPE percentage stabilization.

Time frame:
Baseline, Pre-dose Days 14, 28 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30
Reported as:
Median · percentage stabilization
Parts A and B: Change From Baseline In TTR Stabilization
percentage stabilizationALXN2060
Day 14, Predose97.15 (94.45 to 100.05)
Day 28, Predose97.29 (95.16 to 99.66)
Month 3, Predose99.09 (95.24 to 102.64)
Month 6, Predose98.56 (94.20 to 104.44)
Month 9, Predose96.47 (94.07 to 101.73)
Month 12, Predose100.89 (99.95 to 102.51)
Month 15, Predose97.65 (96.30 to 100.03)
Month 18, Predose96.75 (94.40 to 101.00)
Month 21, Predose101.30 (99.80 to 103.00)
Month 24, Predose102.60 (98.20 to 104.80)
Month 27, Predose102.65 (101.00 to 105.60)
Month 30, Predose95.60 (91.60 to 103.60)
PrimaryAll-cause Mortality (ACM) Over A 30-month Period

ACM was assessed as time from the date of first initiation of study treatment to the date of death during a 30-month period, and was analyzed using Kaplan-Meier analysis. Data are reported for the number of participants with ACM over the 30-month period.

Time frame:
30 months
Reported as:
Count of participants · Participants
All-cause Mortality (ACM) Over A 30-month Period
ParticipantsALXN2060
All-cause Mortality (ACM) Over A 30-month Period0

Adverse events

Collected over Up to approximately Month 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALXN20601/25 (4%)17/25 (68%)25/25 (100%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventALXN2060
Cardiac failure chronicCardiac disorders3/25
Atrioventricular block completeCardiac disorders2/25
Cardiac failureCardiac disorders2/25
Large intestine polypGastrointestinal disorders2/25
BradycardiaCardiac disorders2/25
Atrial fibrillationCardiac disorders1/25
Cardiac discomfortCardiac disorders1/25
Sinus arrestCardiac disorders1/25
Sinus node dysfunctionCardiac disorders1/25
Diverticulum intestinal haemorrhagicGastrointestinal disorders1/25
Most frequent other events
Showing 10 of 44
Most frequent other events
EventALXN2060
ConstipationGastrointestinal disorders8/25
NasopharyngitisInfections and infestations6/25
Back painMusculoskeletal and connective tissue disorders5/25
COVID-19Infections and infestations5/25
PyrexiaGeneral disorders4/25
HaematuriaRenal and urinary disorders4/25
Renal impairmentRenal and urinary disorders4/25
RashSkin and subcutaneous tissue disorders4/25
Benign prostatic hyperplasiaReproductive system and breast disorders3/22
AnaemiaBlood and lymphatic system disorders3/25

Baseline characteristics

Full Analysis Set, which included all participants who have received at least 1 dose of ALXN2060.

Age, Continuous
Age, Continuous(years)ALXN2060
Mean76.5 ± 6.31
Sex: Female, Male
Sex: Female, Male(Participants)ALXN2060
Female3
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ALXN2060
Hispanic or Latino0
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ALXN2060
American Indian or Alaska Native0
Asian25
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

11 sites
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Matsumoto-shi, 390-8621, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Nankoku-shi, 783-8505, Japan
  • Research Site
    Sagamihara-shi, 252-0375, Japan
  • Research Site
    Sapporo, 060-8543, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Suita-shi, 564-8565, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Nov 2023, 35 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2020
First posted
Nov 9, 2020
StartActual
Nov 13, 2020
Primary completionActual
Nov 8, 2023
CompletionActual
Aug 21, 2025
Results first posted
Dec 16, 2024
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04622046
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Nov 13, 2020
Primary completion
Nov 8, 2023
Completion
Aug 21, 2025
Results posted
Dec 16, 2024
Last update
Jun 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acoramidis

Start the discussion